Fibulin-1 interacts with Sex Hormone Binding Globulin and is linked to less aggressive estrogen-dependent breast cancers
In this study we investigated the expression of fibulins, their functional relationship with SHBG and involvement in behavior of estrogen-sensitive breast cancer.Main methodsGene expression of fibulins was performed by Real time-PCR on two estrogen-sensitive breast cancer cell lines, MCF-7 and T47D. Fibulin-1 protein expression and localization were determined by Western blot and immunofluorescence. SHBG interaction with-fibulin-1 was assessed by GST-pull down assay. MCF-7 cell growth and gene expression, after fibulin-1 silencing by siRNA, were evaluated. Finally, the expression of fibulin-1 was correlated to clinical and pathological data of 21 breast cancer tissue samples.Key findingsFibulin-1 was expressed in both cell lines and it was increased by estradiol. SHBG interacted with fibulin-1C; proteins co-localized at MCF-7 cell membranes and SHBG localization at membranes disappeared after silencing fibulin-1. Fibulin-1 silencing, moreover, generated MCF-7 cells unresponsive to estradiol and SHBG and characterized by increased proliferation. Finally, in breast cancer tissue samples expressing fibulin-1 the proliferation index was significantly lower than in fibulin-1 negative samples.SignificanceFibulin-1 interacts with SHBG, it is associated with a less aggressive behavior of breast cancer cells and correlates to a better prognosis of the tumor.
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
This article is licensed under aCreative Commons Attribution-NonCommercial 3.0 Unported Licence.Fay Nicolson, Lauren E. Jamieson, Samuel Mabbott, Konstantinos Plakas, Neil C. Shand, Michael R. Detty, Duncan Graham, Karen Faulds Multiplexed imaging of three nanotags within live breast cancer tumour models through depths of 10 mm using handheld SESORRS. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Condition: Breast Cancer Intervention: Drug: T-DM1 Sponsors: Dana-Farber Cancer Institute; Susan G. Komen Breast Cancer Foundation; Gateway for Cancer Research Not yet recruiting
We describe 2 patients with local recurrence 3 and 9 years, respectively, after mastectomy with DIEAP (deep inferior epigastric artery perforator) flap breast reconstruction. Patients generally present with a palpable mass, pain, or other visible abnormalities. Various imaging techniques are helpful, always completed by biopsy to characterize the tumour. A repeated sentinel node procedure can be useful in staging. The treatment of the local recurrence needs to be determined in a multidisciplinary team consultation.Case Rep Oncol 2018;11:493 –498
Lauren Trintinaglia, Lucas Poitevin Bandinelli, Rodrigo Grassi-Oliveira, Laura Esteves Petersen, Marcelo Anzolin, Bruna Luz Correa, Jaqueline Bohrer Schuch, Mois és Evandro Bauer
BREAST cancer symptoms and signs develop when a few cells in this area start to divide uncontrollably. The most common cancer in women, there are also rare cases of the cancer developing in men. Watch out for these warning signs of breast cancer.
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00392
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.8b03822
Cancers, Vol. 10, Pages 234: Morphomechanical Alterations Induced by Transforming Growth Factor-β1 in Epithelial Breast Cancer Cells Cancers doi: 10.3390/cancers10070234 Authors: Mariafrancesca Cascione Valeria De Matteis Chiara C. Toma Stefano Leporatti The Epithelial to mesenchymal transition (EMT) is the process that drives epithelial tumor cells to acquire an invasive phenotype. The role of transforming growth factor-β1 (TGF-β1) in EMT is still debated. We used confocal laser scanning microscopy and scanning force spectroscopy to perform a morphomechanical analysis on epithelial bre...